Safety Profile Overview
Selective JAK1 inhibitor for RA, atopic dermatitis, UC, and Crohn's. Boxed warning for serious infections, mortality, malignancy, and thrombosis.
Generic Name
upadacitinib
Brand Names
Rinvoq
Therapeutic Class
JAK Inhibitor
Manufacturer
AbbVie
What Pharma Signal Tracks for Rinvoq
- Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Rinvoq, including serious outcomes, hospitalizations, and deaths.
- FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Rinvoq products.
- Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
- Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
- Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
- Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.
Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.
Get Rinvoq Safety Data via API
One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Rinvoq.
curl "https://api.pharma-signal.com/drug/safety/rinvoq" \ -H "X-API-Key: your_key" # Returns risk score, adverse event counts, # serious/death rates, recalls, and signals
Related Safety Intelligence
Pharma Signal provides comparative analysis across therapeutic classes. Compare Rinvoq against other JAK Inhibitor drugs, or explore the full manufacturer portfolio for AbbVie.
- Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
- Therapeutic class benchmarking — See how Rinvoq ranks within JAK Inhibitor on serious event rates.
- Company portfolio risk — View all drugs from AbbVie with aggregate risk exposure.
- AI analyst briefs — Get a natural-language safety assessment combining all data sources.